Esophageal Adenocarcinoma — Trials

Esophageal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 70
Recruiting: 45
Ph III recruiting: 4
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (27)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04210115	Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)	completed	Phase 3	703	Merck Sharp & Dohme LLCINDUSTRY	27	Jul 22, 2026	clinicaltrials
NCT01196390	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	completed	Phase 3	203	National Cancer Institute (NCI)NIH	1	Jun 2, 2026